Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-10. (canceled)

11. (currently amended) A vector comprising a polynucleotide of claim 27 ~~selected from the group consisting of a polynucleotide of claim 5 and a polynucleotide that hybridizes under stringent or moderately stringent hybridization conditions to a polynucleotide of claim 5~~.

12. (currently amended) ~~The~~ A vector ~~of claim 11, further~~ comprising a non-native expression control sequence operably linked to ~~the~~ a polynucleotide selected from the group consisting of a polynucleotide of claim 27 and a polynucleotide of claim 30.

13. (currently amended) A host cell comprising a non-native expression control sequence operably linked to a polynucleotide selected from the group consisting of a polynucleotide of claim 27 and a polynucleotide of claim 30 ~~a vector of claim 11~~.

14-18. (canceled)

19. (currently amended) A method for producing an anthrax toxin receptor, the method ~~including the step~~ comprising the steps of:

transcribing a polynucleotide ~~that encodes a soluble polypeptide that comprises an anthrax toxin receptor~~ operably linked to an upstream expression control sequence, wherein the polynucleotide is selected from the group consisting of a polynucleotide of claim 27 and a polynucleotide of claim 30 ~~the receptor being selected from the group consisting of a soluble, PA-binding fragment of SEQ ID NO:2, a soluble, PA-binding fragment of SEQ ID NO:6, a soluble, PA-binding fragment of SEQ ID NO:8, a soluble, PA-binding fragment of SEQ ID NO:10, and a fusion protein comprising any of the foregoing~~, to produce an mRNA; and

translating the mRNA to produce the anthrax toxin receptor.

20. (original) A method as claimed in Claim 19, wherein the polynucleotide is operably linked to the expression control sequence in an expression vector, and wherein the expression vector is delivered into a host cell, the expression control sequence being operable in the host cell.

21. (original) A method as claimed in Claim 19, wherein at least one of the transcribing and translating steps are performed *in vitro*.

22-26. (canceled)

27. (new) An isolated polynucleotide or complement thereof, the polynucleotide comprising a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ID NO:2, amino acids 27-321 of SEQ ID NO:2, and amino acids 28-320 of SEQ ID NO:2.

28. (new) The isolated polynucleotide of claim 27, wherein the polynucleotide consists of a nucleotide sequence that encodes an amino acid sequence selected from the group consisting of SEQ ID NO:2, amino acids 27-321 of SEQ ID NO:2, and amino acids 28-320 of SEQ ID NO:2.

29. (new) The isolated polynucleotide of claim 27 comprising SEQ ID NO:1 from position 104 to 1207 or the complement thereof.

30. (new) An isolated polynucleotide or complement thereof, the polynucleotide encoding an amino acid sequence selected from the group consisting of amino acids 41-227 of SEQ ID NO:2, amino acids 42-222 of SEQ ID NO:2, and amino acids 44-216 of SEQ ID NO:2.

31. (new) The isolated polynucleotide of claim 30 wherein the polynucleotide encodes an amino acid sequence selected from the group consisting of amino acids 41-227 of SEQ ID NO:2 and amino acids 42-222 of SEQ ID NO:2.